Related Experiment Video
Updated: May 30, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Einat Peles1, Shaul Schreiber, Vera Rados
1Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel. edinatp@tasmc.health.gov.il
Journal of Addiction Medicine
|August 17, 2011
Summary
Hepatitis C virus (HCV) seroconversion is low in methadone maintenance treatment (MMT). Risk factors for HCV infection include younger age, drug injection, and benzodiazepine abuse at MMT admission.
Area of Science:
- Infectious Diseases
- Public Health
- Addiction Medicine
Background:
- Hepatitis C virus (HCV) infection remains a significant global health concern.
- Methadone maintenance treatment (MMT) is a cornerstone for opioid use disorder management.
- Understanding HCV seroconversion dynamics within MMT is crucial for targeted prevention strategies.
Purpose of the Study:
- To identify risk factors associated with hepatitis C virus (HCV) seroconversion among patients admitted to methadone maintenance treatment (MMT).
- To characterize individuals who remained seronegative for HCV upon admission to MMT.
- To inform the development of targeted interventions to reduce HCV transmission in MMT settings.
Main Methods:
- A prospective cohort study followed 657 patients admitted to an MMT clinic in Tel Aviv, Israel, between 1993 and 2008.
- Analysis included 207 patients who were initially HCV negative and had more than one HCV test.
- Risk factors and seroconversion rates were analyzed using statistical methods.
Main Results:
- The overall incidence of HCV seroconversion in MMT was low at 2 per 100 person-years.
- Higher seroconversion rates were observed in younger patients (<30 years), those with a history of drug injection, and those with positive urine tests for benzodiazepines.
- Predictors for seroconversion included younger age at MMT admission, history of drug injection, and benzodiazepine abuse.
Conclusions:
- HCV seroconversion rates are low among patients in MMT, including former USSR immigrants.
- Key predictors for seroconversion are admission-related factors: younger age, drug injection, and benzodiazepine use.
- Targeted interventions are necessary to mitigate HCV transmission in high-risk patient groups within MMT programs.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...